Date:8/27/2009

Cost of products sold 737,230 777,076 1,492,721 1,510,294 Selling and marketing 3,644,796 4,383,802 7,008,802 8,523,989 Research and development 918,460 2,630,725 2,028,402 3,400,842 General and administrative 1,021,639 1,236,435 2,104,733 2,681,298 Amortization of product license right 171,726 171,726 343,452 343,452 Other 25,193 26,733 51,222 54,196 ------ ------ ------ ------ Total costs and expenses 6,519,044 9,226,497 13,029,332 16,514,071 --------- --------- ---------- ---------- Operating income 1,838,488 594,116 3,632,027 2,711,141 Interest income 50,647 10,160 133,019 27,756 Interest expense (10,377) (84,224) (123,981) (181,935) ------- ------- -------- --------- Net income before income taxes 1,878,758 520,052 3,641,065 2,556,962 Income tax expense (820,335) (232,637) (1,187,392) (1,063,696) -------- -------- ----------- ---------- Net income 1,058,423 287,415 2,453,673 1,493,266 Net loss at subsidiary attributable to noncontrolling interests - 8,456 - 20,695 --- ----- --- ------ Net income attributable to common shareholders $1,058,423 $295,871 $2,453,673 $1,513,961 ========== ======== ========== ========== Earnings per share
'/>"/>

SOURCE Cumberland Pharmaceuticals Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13
Related medicine news :

1. Orion ICG, LLC Announces Acquisition of Cumberland Therapy Services, Inc.
2. Cumberland Pharmaceuticals Announces Appointments
3. Cumberland Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 27, 2009
4. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
5. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
6. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
7. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
8. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
9. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
11. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes